ScholarIQanswers from OpenAlex & ORCID
George D. Demetri
ResearcherPublications, citations & collaboration network
George D. Demetri is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does George D. Demetri have?
ScholarIQindexed works
George D. Demetri has 637 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does George D. Demetri have?
ScholarIQcitation count
George D. Demetri has 64,264 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of George D. Demetri?
ScholarIQh-index
George D. Demetri has an h-index of 115 in OpenAlex.
What is the i10-index of George D. Demetri?
ScholarIQi10-index
George D. Demetri has an i10-index of 297 in OpenAlex.
What is the ORCID of George D. Demetri?
ScholarIQorcid
The ORCID for George D. Demetri is on the source record.
What is the OpenAlex record for George D. Demetri?
ScholarIQopenalex
The OpenAlex for George D. Demetri is on the source record.
What are the most-cited papers on George D. Demetri?
ScholarIQmost cited works
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W. T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott M. Schuetze, Hema Sundar, Jonathan C. Trent, Jeffrey D. Wayne
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri, Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Arthur P. Staddon, Mohammed Milhem, A. Elias, Kristen N. Ganjoo, Hussein A. Tawbi, Brian Andrew Van Tine, Alexander I. Spira, Andrew Dean, Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, Trilok Parekh, Robert G. Maki, Shreyaskumar Patel
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Jean‐Yves Blay, Kenneth R. Hande, Mary Lou Keohan, Brian L. Samuels, Scott M. Schuetze, Claudia Lebedinsky, Yusri Elsayed, Miguel Izquierdo, Javier Gómez‐Román, Youn C. Park, Axel Le Cesne
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen Zhao, Katherine A. Cheng, Zandra E. Walton, Yuchuan Wang, Hiromichi Ebi, Takeshi Shimamura, Yan Liu, Tanya Tupper, Jing Ouyang, Jie Li, Peng Gao, Michele Sue‐Ann Woo, Chunxiao Xu, Masahiko Yanagita, Abigail Altabef, Shumei Wang, Charles Lee, Yuji Nakada, Christopher G. Peña, Yanping Sun, Yoko Franchetti, Catherine Yao, Amy Saur, Michael D. Cameron, Mizuki Nishino, D. Neil Hayes, Matthew D. Wilkerson, Patrick J. Roberts, Carrie B. Lee, Nabeel Bardeesy, Mohit Butaney, Lucian R. Chirieac, Daniel B. Costa, David M. Jackman, Norman E. Sharpless, Diego H. Castrillón, George D. Demetri, Pasi A. Jänne, Pier Paolo Pandolfi, Lewis C. Cantley, Andrew L. Kung, Jeffrey A. Engelman, Kwok‐Kin Wong
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Jayesh Desai, Leila Yassa, Ellen Marqusee, Suzanne George, Mary C. Frates, Ming Hui Chen, Jeffrey A. Morgan, Samuel S. Dychter, P. Reed Larsen, George D. Demetri, Erik K. Alexander